+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-alcoholic Steatohepatitis Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 80 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 6090497
Description Jump to:
Non-alcoholic steatohepatitis (NASH) treatments, including vitamin E, obeticholic acid, and resmetirom, address a progressive liver disease driven by obesity (650 million adults globally), type 2 diabetes (537 million cases), and metabolic syndrome. NASH, projected to affect 27 million U.S. patients by 2030, is a leading cause of liver transplants and increases cardiovascular risk by 50%.

The market is propelled by rising prevalence, non-invasive diagnostics improving accuracy by 40%, and accelerated regulatory approvals, such as Rezdiffra in 2024. Government funding, including USD 2.31 billion from NIDDK, and 60% OECD reimbursement coverage further drive growth. The global NASH treatment market is estimated at USD 5.0-9.0 billion in 2025, with a CAGR of 22%-30% through 2030.

Regional Market Trends

  • North America: The U.S. leads with high obesity rates and Rezdiffra adoption, while Canada emphasizes metabolic health programs.
  • Europe: Germany, France, and the UK drive growth with advanced liver disease management and biomarker adoption.
  • Asia Pacific: China and India see rising NASH cases due to lifestyle changes, with Japan focusing on novel therapies.
  • Rest of the World: Brazil expands diagnostic infrastructure, while the Middle East addresses diabetes-related NASH.

Distribution Channel Analysis

  • Hospital Pharmacies: Expected growth of 22.5%-30.5%, driven by novel therapies like resmetirom. Trends focus on specialized liver care.
  • Retail and Specialty Pharmacies: Projected growth of 22.0%-30.0%, linked to outpatient management. Advances emphasize patient access.
  • Other Pharmacies: Anticipated growth of 21.5%-29.5%, covering online platforms. Trends highlight digital prescriptions.

Type Analysis

  • Vitamin E and Pioglitazone: Expected growth of 20.0%-28.0%, used for early-stage NASH. Trends focus on cost-effective options for mild cases.
  • Obeticholic Acid (OCA): Projected growth of 22.5%-30.5%, effective for fibrosis. Advances emphasize regulatory progress and combination therapies.
  • Lanifibranor: Anticipated growth of 23.0%-31.0%, valued for multi-pathway action. Trends highlight metabolic and anti-fibrotic benefits.
  • Semaglutide: Expected growth of 22.8%-30.8%, leveraging weight loss and diabetes synergy. Developments prioritize dual indications.
  • Resmetirom: Expected growth of 24.0%-32.0%, a first-in-class therapy reducing liver fat. Trends focus on transformative outcomes.
  • Aramchol: Expected growth of 21.5%-29.5%, targeting steatosis. Trends highlight potential in combination regimens.
  • Cenicriviroc: Expected growth of 21.0%-29.0%, addressing inflammation. Developments prioritize anti-fibrotic effects.
  • Other Drugs: Expected growth of 20.5%-28.5%, covering pipeline candidates. Trends focus on diverse mechanisms.

Key Market Players

  • Madrigal Pharmaceuticals: Pioneers resmetirom for NASH treatment.
  • Intercept Pharmaceuticals: Develops obeticholic acid for fibrosis.
  • Inventiva: Focuses on lanifibranor for metabolic benefits.
  • Novo Nordisk: Offers semaglutide, leveraging diabetes expertise.
  • Pfizer: Innovates combination therapies for NASH.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Moderate, as high R&D costs and regulatory hurdles exist, but unmet medical needs attract new players.
  • Threat of Substitutes: Moderate, with lifestyle interventions competing, but advanced NASH requires pharmacological solutions.
  • Bargaining Power of Buyers: Moderate, as insurers negotiate prices, but limited approved therapies strengthen providers.
  • Bargaining Power of Suppliers: Low, with multiple suppliers of active pharmaceutical ingredients.
  • Competitive Rivalry: High, with companies competing on efficacy, safety, and speed to market.

Market Opportunities and Challenges

Opportunities:

  • Addressing NASH, projected to affect 27 million U.S. patients by 2030.
  • Leveraging obesity and diabetes, impacting 650 million and 537 million people, respectively.
  • Utilizing non-invasive diagnostics, improving accuracy by 40%.
  • Benefiting from USD 2.31 billion NIDDK funding for research.
  • Expanding 60% OECD reimbursement coverage for NASH therapies.
  • Developing combination therapies for comprehensive management.

Challenges:

  • High costs of novel therapies limiting patient access.
  • Regulatory delays for pipeline drugs.
  • Limited NASH awareness and diagnostics in developing regions.
  • Competition from lifestyle-based interventions.
  • Complexity in managing advanced NASH and comorbidities.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Non-Alcoholic Steatohepatitis Treatment Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in North America (2020-2030)
8.1 Non-Alcoholic Steatohepatitis Treatment Market Size
8.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
8.3 Competition by Players/Suppliers
8.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in South America (2020-2030)
9.1 Non-Alcoholic Steatohepatitis Treatment Market Size
9.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
9.3 Competition by Players/Suppliers
9.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in Asia & Pacific (2020-2030)
10.1 Non-Alcoholic Steatohepatitis Treatment Market Size
10.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
10.3 Competition by Players/Suppliers
10.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in Europe (2020-2030)
11.1 Non-Alcoholic Steatohepatitis Treatment Market Size
11.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
11.3 Competition by Players/Suppliers
11.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in MEA (2020-2030)
12.1 Non-Alcoholic Steatohepatitis Treatment Market Size
12.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
12.3 Competition by Players/Suppliers
12.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Non-Alcoholic Steatohepatitis Treatment Market (2020-2025)
13.1 Non-Alcoholic Steatohepatitis Treatment Market Size
13.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
13.3 Competition by Players/Suppliers
13.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Chapter 14 Global Non-Alcoholic Steatohepatitis Treatment Market Forecast (2025-2030)
14.1 Non-Alcoholic Steatohepatitis Treatment Market Size Forecast
14.2 Non-Alcoholic Steatohepatitis Treatment Application Forecast
14.3 Competition by Players/Suppliers
14.4 Non-Alcoholic Steatohepatitis Treatment Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Madrigal Pharmaceuticals
15.1.1 Company Profile
15.1.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.1.3 SWOT Analysis of Madrigal Pharmaceuticals
15.1.4 Madrigal Pharmaceuticals Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.2 Intercept Pharmaceuticals
15.2.1 Company Profile
15.2.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.2.3 SWOT Analysis of Intercept Pharmaceuticals
15.2.4 Intercept Pharmaceuticals Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.3 Inventiva
15.3.1 Company Profile
15.3.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.3.3 SWOT Analysis of Inventiva
15.3.4 Inventiva Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.4 Nordisk
15.4.1 Company Profile
15.4.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.4.3 SWOT Analysis of Nordisk
15.4.4 Nordisk Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.5 Galmed Pharmaceuticals
15.5.1 Company Profile
15.5.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.5.3 SWOT Analysis of Galmed Pharmaceuticals
15.5.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.6 Galectin Therapeutics
15.6.1 Company Profile
15.6.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.6.3 SWOT Analysis of Galectin Therapeutics
15.6.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.7 Pfizer
15.7.1 Company Profile
15.7.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
15.7.3 SWOT Analysis of Pfizer
15.7.4 Pfizer Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Non-Alcoholic Steatohepatitis Treatment Report
Table Data Sources of Non-Alcoholic Steatohepatitis Treatment Report
Table Major Assumptions of Non-Alcoholic Steatohepatitis Treatment Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Non-Alcoholic Steatohepatitis Treatment Picture
Table Non-Alcoholic Steatohepatitis Treatment Classification
Table Non-Alcoholic Steatohepatitis Treatment Applications
Table Drivers of Non-Alcoholic Steatohepatitis Treatment Market
Table Restraints of Non-Alcoholic Steatohepatitis Treatment Market
Table Opportunities of Non-Alcoholic Steatohepatitis Treatment Market
Table Threats of Non-Alcoholic Steatohepatitis Treatment Market
Table COVID-19 Impact For Non-Alcoholic Steatohepatitis Treatment Market
Table Raw Materials Suppliers
Table Different Production Methods of Non-Alcoholic Steatohepatitis Treatment
Table Cost Structure Analysis of Non-Alcoholic Steatohepatitis Treatment
Table Key End Users
Table Latest News of Non-Alcoholic Steatohepatitis Treatment Market
Table Merger and Acquisition
Table Planned/Future Project of Non-Alcoholic Steatohepatitis Treatment Market
Table Policy of Non-Alcoholic Steatohepatitis Treatment Market
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size
Figure 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 North America Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
Table 2020-2025 North America Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2030 United States Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Canada Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Mexico Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size
Figure 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 South America Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
Table 2020-2025 South America Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2030 Brazil Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Argentina Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Chile Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Peru Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size
Figure 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2030 China Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 India Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Japan Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Southeast Asia Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Australia Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size
Figure 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2030 Germany Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 France Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 United Kingdom Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Italy Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Spain Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Belgium Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Netherlands Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Austria Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Poland Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Russia Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size
Figure 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2030 Egypt Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Israel Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 South Africa Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Gulf Cooperation Council Countries Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2030 Turkey Non-Alcoholic Steatohepatitis Treatment Market Size
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size Share by Region
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Application
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Revenue
Figure 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth Rate
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Market Share
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Type
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size Share by Region
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Application
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Application
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Revenue
Figure 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth Rate
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Market Share
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Type
Table 2025-2030 Non-Alcoholic Steatohepatitis Treatment Global Market Share by Type

Companies Mentioned

  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals
  • Inventiva
  • Nordisk
  • Galmed Pharmaceuticals
  • Galectin Therapeutics
  • Pfizer

Related Topics

Related Reports

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 110 Pages
  • Global
From
Non-Alcoholic Steatohepatitis Treatment Market Report 2025 - Product Image

Non-Alcoholic Steatohepatitis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Market Report 2025 - Product Image

Non-Alcoholic Steatohepatitis (NASH) Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Non-Alcoholic Steatohepatitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Non-Alcoholic Steatohepatitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Non-alcoholic Steatohepatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology - Product Image

Non-alcoholic Steatohepatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

  • Report
  • 104 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.